Short Interest in Entero Therapeutics, Inc. (NASDAQ:ENTO) Declines By 31.3%

Entero Therapeutics, Inc. (NASDAQ:ENTO) was the recipient of a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 96,000 shares, a decrease of 31.3% from the February 13th total of 139,800 shares. Currently, 2.1% of the shares of the company are short sold. Based on an average daily trading volume, of 309,400 shares, the short-interest ratio is presently 0.3 days.

Entero Therapeutics Stock Performance

NASDAQ:ENTO opened at $0.53 on Tuesday. The stock’s 50 day moving average price is $0.53 and its two-hundred day moving average price is $0.52. Entero Therapeutics has a 12-month low of $0.19 and a 12-month high of $3.16.

About Entero Therapeutics

Entero Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis.